Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

NCT04124731 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

98

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma
Non-small Cell Lung Cancer

Interventions

DRUG: sintilimab plus anlotinib
DRUG: Chemotherapy

Sponsor

Shanghai Chest Hospital